Summary
The aim of this Phase 1b/2 study is to investigate the safety, efficacy, and
pharmacokinetics (PK) of a single dose of LS301-IT, a novel fluorescence imaging agent
developed by Integro Theranostics (IT), administered by intravenous (IV) injection in
female patients undergoing partial mastectomy for DCIS (whether or not undergoing planned
SLNB) or Stage I-II primary invasive breast cancer undergoing SLNB. Safety is the primary
objective of this study, followed by efficacy that will be assessed from fluorescence
imaging observations and data.